FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma
Although FRONTIER-3 did not meet the primary study end-point, tozorakimab treatment showed encouraging efficacy signals in patients with early-onset asthma and a history of exacerbations.
Authors
- Maria G. Belvisi (ORCID: https://orcid.org/0000-0003-1652-4370)
- Chris Kell
- Rachel Moate
- Jonathan Corren (ORCID: https://orcid.org/0000-0001-5951-3239)
- Muhammad Waqas Sadiq (ORCID: https://orcid.org/0000-0003-3331-0702)
- Fred Reid
- Sophia Cameron‐Christie (ORCID: https://orcid.org/0000-0001-7123-9631)
- Daniel Muthas (ORCID: https://orcid.org/0000-0001-9320-2004)
- Benjamin Georgi
- Mateusz Rytelewski
- Adam Platt (ORCID: https://orcid.org/0009-0008-0109-7699)
- Hitesh Pandya (ORCID: https://orcid.org/0000-0003-0514-2529)
- Eva Lindqvist
- Adam Williams (ORCID: https://orcid.org/0009-0002-8127-3408)
- Dennis E. Brooks
- Eulalia Jiménez (ORCID: https://orcid.org/0009-0006-4351-8063)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of California, Los Angeles (US)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Imperial College London (GB)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1183/23120541.00183-2025
- Citations
- 2
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- AstraZeneca